Case commentary: Bailey v GlaxoSmithKline UK Ltd [2017] EWHC 3195 (QB)
Alison Kirby analyses this judgment in which the High Court has considered, for the first time, whether the Arkin cap - the principle that a funder’s potential liability for adverse costs will be limited to the amount of the funding provided - still fits.
This is premium content
In order to access this content you must be a member of the Civil Litigation Section and logged in.
If you have not registered before, register now to gain access to this content. You must use the email associated with your section membership.
Log inNot a Civil Litigation Section Member?
Join nowif you require assistance with joining this section, please email us at msadmin@lawsociety.org.uk or call us on 020 733 804